Tumor targeting with biotinylated tumor necrosis factor α: Structure- activity relationships and mechanism of action on avidin pretargeted tumor cells

Cancer Research

Volumn 58, Issue 17, 1998, Pages 3866-3872

  Corti, Angelo ^a   Gasparri, Anna ^a   Sacchi, Angelina ^a   Curnis, Flavio ^a   Sangregorio, Romina ^a   Colombo, Barbara ^a   Siccardi, Antonio G ^a   Magni, Fulvio ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AVIDIN; BIOTIN; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN BINDING; ARTICLE; BINDING SITE; BIOTINYLATION; CYTOLYSIS; HUMAN; HUMAN CELL; IMMUNOCHEMISTRY; MELANOMA CELL; PRIORITY JOURNAL; TUMOR CELL; TUMOR CELL CULTURE;

ANIMALS; AVIDIN; BINDING SITES; BIOTIN; HUMANS; MELANOMA; MICE; NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032170537     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., and Williamson, B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA, 72: 3666-3670, 1975.
2. Helson, L., Green, S., Carswell, E., and Old, L. J. Effect of tumor necrosis factor on cultured human melanoma cells. Nature (Lond.), 258: 731-732, 1975.
3. Fiers, W. Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level. FEBS Lett., 285: 199-212, 1991.
4. Sidhu, R. S., and Bollon, A. P. Tumor necrosis factor activities and cancer therapy: a perspective. Pharmacol. Ther, 57: 79-128, 1993.
5. Corti, A., Fassina, G., Marcucci, F., Barbanti, E., and Cassani, G. Oligomeric tumour necrosis factor-α slowly converts into inactive forms at bioactive levels. Biochem. J., 284: 905-910, 1992.
6. Vandenabeele, P., Declercq, W., Beyaert, R., and Fiers, W. Two tumor necrosis factor receptors: structure and function. Trends Cell Biol., 5: 392-399, 1995.
7. Fiers, W. Biologic therapy with TNF-α: preclinical studies. In: V. De Vita, S. Hellman, and S. Rosenberg (eds.), Biologic Therapy of Cancer: Principles and Practice, pp. 295-327. Philadelphia: J. B. Lippincott Co., 1995.
8. Fraker, D. L., and Alexander, H. R. Biologic therapy with TNF-α: systemic administration and isolation-perfusion. In: V. De Vita, S. Hellman, and S. Rosenberg (eds.), Biologic Therapy of Cancer: Principles and Practice, pp. 329-345. Philadelphia: J. B. Lippincott Co., 1995.
9. Lienard, D., Eggermont, A. M., Schraffordt Koops, H., Kroon, B. B., Rosenkaimer, F., Autier, P., and Lejeune, F. J. Isolated perfusion of the limb with high-dose tumour necrosis factor-α (TNF-α), interferon-γ (IFN-γ) and melphalan for melanoma stage III. Results of a multi-centre pilot study. Melanoma Res., 4: 21-26, 1994.
10. Lejeune, F. J., Lienard, D., Leyvraz, S., and Mirimanoff, R. O. Regional therapy of melanoma. Eur. J. Cancer, 29A: 606-612, 1993.
11. Lienard, D., Ewalenko, P., Delmotte, J. J., Renard, N., and Lejeune, F. J. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. Clin. Oncol., 10: 52-60, 1992.
12. Corti, A., and Marcucci, F. Tumor necrosis factor: strategies for improving the therapeutic index. Drug Target., in press, 1998.
13. Moro, M., Pelagi, M., Fulci, G., Paganelli, G., Dellabona, P., Casorati, G., Siccardi, A. G., and Corti, A. Tumor cell targeting with antibody-avidin complexes and biotinylated tumor necrosis factor-α. Cancer Res., 57: 1922-1928, 1997.
14. Paganelli, G., Magnani, P., Zito, F., Villa, E., Sudati, F., Lopalco, L., Rossetti, C., Malcovati, M., Chiolerio, F., Seccamani, E., Siccardi, A. G., and Fazio, F. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res., 51: 5960-5966, 1991.
15. Grana, C., Chinol, M., Magnani, P., Corti, A., Sidoli, A., Siccardi, A., and Paganelli, G. In vivo tumor targeting based on the avidin-biotin system. Tumor Target., 2: 230-239, 1996.
16. Goodwin, D. A. Tumor pretargeting: almost the bottom line. J. Nucl. Med., 36: 876-879, 1995.
17. Siccardi, A. G., Paganelli, G., Pontiroli, A. E., Pelagi, M., Magnani, P., Viale, G., Faglia, G., and Fazio, F. In viva imaging of chromogranin A-positive tumours by three-step monoclonal antibody targeting. Eur. J. Nucl. Med., 23: 1455-1459, 1996.
18. Corti, A., Poiesi, C., Merli, S., and Cassani, G. TNF-α quantification by ELISA and bioassay: effects of TNF-α-soluble TNF receptor (p55) complex dissociation during assay incubation. J. Immunol. Methods, 177: 191-198, 1994.
19. Schmid, J. A., and Billich, A. Simple method for high sensitivity chemiluminescence ELISA using conventional laboratory equipment. Biotechniques, 22: 278-280, 1997.
20. Smith, R. A., and Baglioni, C. The active form of tumor necrosis factor is a trimer. J. Biol. Chem., 262: 6951-6954, 1987.
21. Ostle, B. Statistics in Research, Ed. 2. Ames, IA: Iowa State University Press, 1963.
22. Green, N. Avidin and streptavidin. Methods Enzymol., 184: 51-67, 1990.
23. Tijssen, P. Practice and Theory of Enzyme Immunoassays, Ed. 1, Vol. 15, p. 305-308. Amsterdam: Elsevier, 1987.
24. Paganelli, G., Magnani, P., Siccardi, A., and Fazio, F. Clinical application of the avidin-biotin system for tumor targeting. In: D. Goldenberg (ed.), Cancer Therapy with Radiolabeled Antibodies, pp. 239-253. Boca Raton: CRC Press, 1995.
25. Poiesi, C., Albertini, A., Ghielmi, S., Cassani, G., and Corti, A. Kinetic analysis of TNF-α oligomer-monomer transition by surface plasmon resonance and immunochemical methods. Cytokine, 5: 539-545, 1993.